candesartan cilexetil has been researched along with Bright Disease in 8 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective, randomised, double-blind, parallel-group, dose-response trial was conducted to investigate the antiproteinuric effect of candesartan cilexetil, the angiotensin II type 1 receptor blocker, in patients with chronic glomerulonephritis." | 9.10 | Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. ( Abe, K; Arakawa, M; Kikkawa, R; Kurokawa, K; Ogawa, N; Onoyama, K; Saruta, T; Tomita, K; Ueda, N, 2002) |
| "To examine the role of the angiotensin II (ATII) type 1a receptor (AT1-R) pathway in renal tissue damage and repair, we investigated reversible glomerular injury in a mouse model of habu snake venom (HSV)-induced glomerulonephritis using AT1-R-deficient (AT1a-/-) mice and AT1-R antagonist-treated mice." | 7.78 | Glomerular repair retardation via blocking of angiotensin II type 1a receptor pathway in a mouse glomerulonephritis model. ( Abe, K; Abe, S; Furusu, A; Hayashi, W; Io, K; Kohno, S; Koji, T; Miyazaki, M; Nishino, T; Obata, Y; Sugaya, T, 2012) |
| "In this prospective, parallel, open study of 86 patients with CGN, we compared the effects on proteinuria and renal functions of 36 months with comparable blood pressure (BP) control achieved by candesartan cilexetil (candesartan, 4-12 mg/day) or benazepril hydrochrolide (benazepril, 2." | 5.13 | Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis. ( Fujiwara, H; Minatoguchi, S; Mori-Takeyama, U; Murata, I; Oda, H; Ohashi, H; Ohno, M; Ozaki, Y, 2008) |
| "A prospective, randomised, double-blind, parallel-group, dose-response trial was conducted to investigate the antiproteinuric effect of candesartan cilexetil, the angiotensin II type 1 receptor blocker, in patients with chronic glomerulonephritis." | 5.10 | Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. ( Abe, K; Arakawa, M; Kikkawa, R; Kurokawa, K; Ogawa, N; Onoyama, K; Saruta, T; Tomita, K; Ueda, N, 2002) |
| "To examine the role of the angiotensin II (ATII) type 1a receptor (AT1-R) pathway in renal tissue damage and repair, we investigated reversible glomerular injury in a mouse model of habu snake venom (HSV)-induced glomerulonephritis using AT1-R-deficient (AT1a-/-) mice and AT1-R antagonist-treated mice." | 3.78 | Glomerular repair retardation via blocking of angiotensin II type 1a receptor pathway in a mouse glomerulonephritis model. ( Abe, K; Abe, S; Furusu, A; Hayashi, W; Io, K; Kohno, S; Koji, T; Miyazaki, M; Nishino, T; Obata, Y; Sugaya, T, 2012) |
| "Perindopril was stopped after the 8-week administration of the two drugs." | 1.32 | [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis]. ( Amemiya, M; Ando, Y; Asano, Y; Honma, S; Iimura, O; Kusano, E; Muto, S; Tanba, K; Yanagiba, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, W | 1 |
| Obata, Y | 1 |
| Nishino, T | 1 |
| Abe, S | 1 |
| Io, K | 1 |
| Furusu, A | 1 |
| Abe, K | 2 |
| Miyazaki, M | 1 |
| Sugaya, T | 1 |
| Koji, T | 1 |
| Kohno, S | 1 |
| Kurokawa, K | 1 |
| Saruta, T | 1 |
| Arakawa, M | 1 |
| Kikkawa, R | 1 |
| Ueda, N | 1 |
| Onoyama, K | 1 |
| Tomita, K | 1 |
| Ogawa, N | 1 |
| Iimura, O | 1 |
| Kusano, E | 1 |
| Tanba, K | 1 |
| Yanagiba, S | 1 |
| Amemiya, M | 1 |
| Ando, Y | 1 |
| Honma, S | 1 |
| Muto, S | 1 |
| Asano, Y | 1 |
| Mori-Takeyama, U | 1 |
| Minatoguchi, S | 1 |
| Murata, I | 1 |
| Fujiwara, H | 1 |
| Ozaki, Y | 1 |
| Ohno, M | 1 |
| Oda, H | 1 |
| Ohashi, H | 1 |
| Yayama, K | 2 |
| Makino, J | 1 |
| Takano, M | 2 |
| Okamoto, H | 2 |
| Matsui, T | 1 |
| Hayashi, K | 1 |
| Nagamatsu, T | 1 |
| Suzuki, Y | 2 |
| Shibouta, Y | 1 |
| Chatani, F | 1 |
| Ishimura, Y | 1 |
| Sanada, T | 1 |
| Ohta, M | 1 |
| Inada, Y | 1 |
| Nishikawa, K | 1 |
| Shirato, I | 1 |
| Okumura, K | 1 |
| Ravetch, JV | 1 |
| Takai, T | 1 |
| Tomino, Y | 1 |
| Ra, C | 1 |
2 trials available for candesartan cilexetil and Bright Disease
| Article | Year |
|---|---|
Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2002 |
Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzazepines; Benzimidazoles; Biphenyl Compounds; Bl | 2008 |
6 other studies available for candesartan cilexetil and Bright Disease
| Article | Year |
|---|---|
Glomerular repair retardation via blocking of angiotensin II type 1a receptor pathway in a mouse glomerulonephritis model.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2012 |
[Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2003 |
Role of angiotensin II in the transforming growth factor-beta 1 expression of rat kidney in anti-glomerular basement membrane antiserum-induced glomerulonephritis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Basement Membrane; Benzimidazoles; Biphen | 1995 |
Activation of the renin-angiotensin system in anti-glomerular basement membrane antibody-induced glomerulonephritis.
Topics: Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Antibodies; Basement Membrane; Benzimida | 1995 |
TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 1996 |
Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis.
Topics: Actins; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Basement Membrane; Benzimidazoles | 1998 |